Eisai Limited (Headquarters: London, Managing Director: Paul Hooper), a U.K. subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo, President: Haruo Naito) announced that Eisai Limited received approval for on-demand therapy of PARIET for moderate to very severe symptomatic gastro-oesophageal reflux disease (symptomatic GORD) through the European Union's (E.U.) Mutual Recognition Procedure (MRP). The European countries involved in the MRP are expected to issue formal amendments to their marketing authorizations in the coming months.
PARIET is currently approved for symptomatic GORD treatment in the E.U. With "on-demand" therapy, patients whose symptomatic GORD had previously been treated successfully would take PARIET 10 mg once daily whenever a heartburn episode recurred until the symptoms are relieved.
PARIET was launched in the E.U. in 1998. Among European countries, Eisai and Janssen-Cilag co-promote PARIET in the United Kingdom, Germany, and Spain. Janssen-Cilag promotes the product in all other European countries. PARIET was first launched in 1997 in Japan, and it was launched as ACIPHEX in 1999 in the United States. Currently, the product has been launched in 70 countries worldwide.
Eisai has been committed to bringing new treatments in gastroenterology since its foundation and will continue to contribute to the treatment of patients with acid related diseases.